Overview
flowchart TD
companies_daiwa_sangyo["Daiwa Sangyo Co., Ltd."]
style companies_daiwa_sangyo fill:#4fc3f7,stroke:#333,color:#000
companies_daiwa_sang_0["Focus Areas"]
companies_daiwa_sangyo -->|"includes"| companies_daiwa_sang_0
style companies_daiwa_sang_0 fill:#81c784,stroke:#333,color:#000
companies_daiwa_sang_1["Manufacturing Capabilities"]
companies_daiwa_sangyo -->|"includes"| companies_daiwa_sang_1
style companies_daiwa_sang_1 fill:#ef5350,stroke:#333,color:#000
companies_daiwa_sang_2["Custom Synthesis Services"]
companies_daiwa_sangyo -->|"includes"| companies_daiwa_sang_2
style companies_daiwa_sang_2 fill:#ffd54f,stroke:#333,color:#000
companies_daiwa_sang_3["Scale and Capacity"]
companies_daiwa_sangyo -->|"includes"| companies_daiwa_sang_3
style companies_daiwa_sang_3 fill:#ce93d8,stroke:#333,color:#000
companies_daiwa_sang_4["Neurodegeneration Drug Support"]
companies_daiwa_sangyo -->|"includes"| companies_daiwa_sang_4
style companies_daiwa_sang_4 fill:#4fc3f7,stroke:#333,color:#000
companies_daiwa_sang_5["Strategic Drug Development Support"]
companies_daiwa_sangyo -->|"includes"| companies_daiwa_sang_5
style companies_daiwa_sang_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Daiwa Sangyo Co., Ltd. (大和産業株式会社) is a Japanese pharmaceutical intermediate and contract manufacturing organization (CMO) headquartered in Tokyo, with manufacturing facilities in the Osaka region. Founded in 1975, the company has evolved from a regional chemical supplier to a critical partner in Japan's pharmaceutical supply chain, specializing in high-potency intermediates and custom synthesis for central nervous system (CNS) drugs["@daiwa_co"].
Unlike companies focused on finished drug products, Daiwa Sangyo operates as a B2B supplier providing pharmaceutical intermediates and active pharmaceutical ingredient (API) building blocks to major Japanese pharmaceutical companies including Takeda Pharmaceutical, Eisai, Astellas Pharma, and Mitsubishi Tanabe Pharma. This position in the supply chain places them at the foundation of Japan's neurodegeneration drug development ecosystem.
Focus Areas
- [Pharmaceutical](/companies) intermediates manufacturing for CNS disorders
- Custom synthesis and process development
- Contract manufacturing (CMO) services
- High-potency and controlled substance intermediates
- Scale-up from gram to metric-ton quantities
- Regulatory support for global submissions
Manufacturing Capabilities
Daiwa Sangyo operates GMP-certified manufacturing facilities in Japan, serving as a critical supply chain node for CNS drug development across Japan[@pmda_guide]. Their capabilities span:
Custom Synthesis Services
The company provides custom synthesis services for pharmaceutical companies developing new CNS drugs, including:
- Alzheimer's disease drug intermediates: Building blocks for [amyloid-beta](/proteins/amyloid-beta) targeting compounds, BACE inhibitors, and anti-tau therapies. Daiwa Sangyo has supplied key intermediates for programs developed by Eisai and Takeda[@takeda_cmo].
- Parkinson's disease therapies: Intermediates for dopamine agonists (pramipexole, ropinirole analogues), MAO-B inhibitors (selegiline, rasagiline), and COMT inhibitors[@cns_intermediates].
- Novel CNS drug delivery systems: Partnerships for nanoparticle and liposomal formulation components targeting the [blood-brain barrier](/entities/blood-brain-barrier).
Scale and Capacity
| Capability | Scale | Application |
|------------|-------|-------------|
| Custom synthesis | Gram to metric tons | Early to late-stage clinical |
| Process development | Lab to pilot scale | Process optimization and validation |
| Scale-up | Pilot to commercial scale | Manufacturing transfer and tech transfer |
| Regulatory support | Pre-IND to NDA | Japanese PMDA, US FDA, EU EMA submissions |
Neurodegeneration Drug Support
Daiwa Sangyo's role in neurodegeneration research extends beyond simple supply:
Strategic Drug Development Support
The company has established long-term supply agreements with major Japanese pharmaceutical companies that are active in neurodegeneration drug development. Through AMED-funded research programs, Daiwa Sangyo supports the development of novel CNS drugs by providing critical intermediates that would otherwise require importation or complex synthesis routes[@amed_cns].
- Anti-amyloid agents: Intermediates for antibody drug conjugates and small molecules targeting amyloid-beta aggregation
- Neurotrophic factors: Precursor molecules for growth factor mimetics
- Ion channel modulators: Building blocks for calcium channel blockers and sodium channel modulators targeting excitotoxicity
- Anti-inflammatory agents: Intermediates for NLRP3 inflammasome inhibitors and cytokine-targeting molecules
- Mitochondrial protectants: Precursors for CoQ10 analogues and MitoQ-style mitochondrial targeted compounds
Quality and Regulatory Compliance
Daiwa Sangyo maintains comprehensive quality certifications supporting global pharmaceutical regulatory requirements:
| System | Certification | Scope |
|--------|---------------|-------|
| GMP (Japan) | PMDA compliance | Manufacturing of pharmaceutical intermediates |
| GMP (US) | FDA 21 CFR 210/211 | API and intermediate manufacturing |
| GMP (EU) | EMA ICH Q7 | European market supply |
| ISO 9001 | JIS Q 9001 | Quality management systems |
| ISO 14001 | JIS Q 14001 | Environmental management |
The company's quality control laboratories perform comprehensive testing including high-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), nuclear magnetic resonance (NMR), and impurity profiling to meet pharmaceutical regulatory standards across Japan, the US, and Europe.
Business Model
Daiwa Sangyo operates on a B2B model serving:
- Major pharmaceutical companies: Long-term supply agreements with Takeda, Astellas, Eisai, and Mitsubishi Tanabe for bulk intermediates
- Japanese biotech companies: Custom synthesis for clinical-stage programs from companies like Kinevo, CureApp, and Peptidream
- Generic manufacturers: API supply for off-patent CNS drugs
- Academic institutions: Research quantities for university-based drug discovery programs
The company's strategic focus on high-potency and controlled substances provides differentiation from commodity chemical suppliers, as these materials require specialized handling, dedicated facilities, and strict regulatory compliance.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)
- [Peptidream Inc.](/companies/peptidream)
- [Kinevo Inc.](/institutions/kinevo-inc)